OctoPlus signs drug development contract with The Medicines Company

OctoPlus signs drug development contract with The Medicines Company

Jul 12, 2010 (Thomson Reuters ONE via COMTEX) -- OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today that it has signed a pharmaceutical development and manufacturing contract with a new client, US-based The Medicines Company. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.

Under the contract terms, OctoPlus will perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.

Suggested Articles

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.